Many studies have shown that primary prostate cancers are multifocal 1-3 and are composed of multiple genetically distinct cancer cell clones 4-6 . Whether or not multiclonal primary prostate cancers typically give rise to multiclonal or monoclonal prostate cancer metastases is largely unknown, although studies at single chromosomal loci are consistent with the latter case.
Many studies have shown that primary prostate cancers are multifocal [1] [2] [3] and are composed of multiple genetically distinct cancer cell clones [4] [5] [6] . Whether or not multiclonal primary prostate cancers typically give rise to multiclonal or monoclonal prostate cancer metastases is largely unknown, although studies at single chromosomal loci are consistent with the latter case.
Here we show through a high-resolution genome-wide single nucleotide polymorphism and copy number survey that most, if not all, metastatic prostate cancers have monoclonal origins and maintain a unique signature copy number pattern of the parent cancer cell while also accumulating a variable number of separate subclonally sustained changes. We find no relationship between anatomic site of metastasis and genomic copy number change pattern. Taken together with past animal and cytogenetic studies of metastasis 7 and recent single-locus genetic data in prostate and other metastatic cancers [8] [9] [10] , these data indicate that despite common genomic heterogeneity in primary cancers, most metastatic cancers arise from a single precursor cancer cell. This study establishes that genomic archeology of multiple anatomically separate metastatic cancers in individuals can be used to define the salient genomic features of a parent cancer clone of proven lethal metastatic phenotype.
We isolated DNA from 94 anatomically separate cancer sites in 30 men who died from metastatic prostate cancer ( Fig. 1a) and analyzed it by chromosomal metaphase-based comparative genomic hybridization (cCGH), Affymetrix Genome-Wide Human SNP (single nucleotide polymorphism) Array 6.0 analysis (Affy6) or both.
We studied 85 sites from 29 of the subjects by cCGH. To assess possible clonal relationships of metastasizing cells, we studied two or more anatomically separate cancerous lesions by cCGH in 24 subjects (80 samples, range two to eight samples per subject). We used significance analysis of microarrays (SAM) 11 to detect 218 loci across the genome that were affected by either copy number gain or loss. We analyzed copy number data from these 218 loci for the 80 samples by unsupervised hierarchical clustering ( Fig. 1b) . For 15 of 24 subjects (63%), cCGH data from all samples clustered by subject of origin, suggesting a strong clonal relationship of separate metastatic samples in the majority of subjects.
Subject-specific 'perfect' clustering of metastatic cCGH copy number data in a substantial number (15 of 24) of the subjects with multiple anatomically separate samples led us to explore this association through an unsupervised cluster-subject matching test, a supervised classification-based assessment [12] [13] [14] and a distance-based analysis, all of which rejected the null hypothesis that observed clustering is random ( Supplementary Figs. 1-3 and Supplementary Methods online).
To better visualize the relationships of the copy number data among the 80 samples studied, we displayed the full cCGH dataset via the top discriminatory components in three-dimensional euclidean space extracted by weighted Fisher criterion-based discriminatory component analysis (wFC-DCA) 15 , where the overall intrasubject copy number pattern similarity of both clustering cases (for example, case 17) and nonclustering cases (for example, case 33) is apparent ( Fig. 1c ). Taken together with the cCGH data clustering results, these data suggest that in the majority of cases metastatic cells in a given subject may have clonal origins.
To further examine potential clonal origins, we performed Affy6 analysis in a subset of samples from 14 subjects in whom at least three metastatic deposits were available for analysis ( Fig. 1 ). Affy6 genomic position resolution is approximately 5,000Â cCGH resolution, with an average physical distance of B700 base pairs between a total of over 1.8 million probes. We observed subject-specific perfect clustering for all 58 samples studied from the 14 subjects ( Fig. 1e ). Permutationbased statistical analyses similar to those performed for the cCGH results showed evidence to reject the null hypothesis of random subject-specific clustering (Supplementary Figs. 4-6 and © 2009 Nature America, Inc. All rights reserved.
Supplementary Methods). Notably, projection of the discriminatory component analysis results for the Affy6 data ( Fig. 1d) shows a tighter and more 'exclusive' association among anatomically distinct cancer samples from the same subject than that seen in the cCGH data ( Fig. 1c ), suggesting that misclustering of samples in the cCGH data is probably due to lower assay resolution.
Analysis of the probability of common individual origins of DNA samples is now relatively routine. Proving common origins of different populations of mutant cells from the same individual is not routine, but it has long been a topic of inquiry in relation to the origins of metastatic cancer 16 . Previous analysis of cytogenetic, isoenzyme and X-chromosome inactivation 9, 17, 18 data, as well as cell line-based experimental metastasis studies 7, 9 and more recent specific analyses of one or a few genetic loci (including PTEN (encoding phosphatase and tensin homolog) and TMPRSS2 (encoding transmembrane protease, serine 2)-ETS transcription factor gene family aberrations), have suggested clonal origins of metastatic melanoma and prostate cancers [8] [9] [10] 19, 20 in at least a substantial percentage of individuals with metastatic cancer.
We further tested the hypothesis that metastatic prostate cancers have clonal origins by examining allele-specific patterns of gain and loss and regions of the genome affected by homozygous deletion.
We analyzed a representative sample of allele-specific copy number data from two subjects ( Figs. 2 and 3) . A signature pattern of copy number gains and losses was present in each sample studied, and elements of this signature were present in every anatomically separate cancer DNA sample. Changes present in all samples for a given subject are here termed omniclonal, and other changes, termed subclonal, were present in only a subset of samples studied in a given subject. chromosomal position and copy number strongly suggests that all metastatic cancer cells in these subjects had a single clonal cancer cell origin, and suggest that studies of multiple metastases in people with cancer can be used to derive a set of changes present in the ultimate parent cancer cell. The presence of omniclonal and subclonal changes (Figs. 1e, 2 and 3) provides a picture of strikingly high-fidelity maintenance of a subject-specific signature set of copy number changes derived from a single parent cancer cell, with variable degrees of additional subclonally maintained changes. Examination of the spectrum of copy number changes at the macro level also suggests definable 'personalities' of omniclonal and subclonal changes among subjects, with, for example, a moderate number of medium-sized omniclonal changes and rare subclonal changes in subject 17, relatively sparse omniclonal changes in subject 19 with relatively greater numbers of subclonal changes, and a high number of relatively small omniclonal changes in subject 33 with a moderate number of subclonal changes ( Fig. 1e ).
We found 17 homozygous deletions unique in chromosomal position and unique to one (with the exception of PTEN and PP2R2A) of the ten study subjects in which they were found (Supplementary Table  1 online). Fifteen of seventeen (88%) of these homozygous deletions were present in all samples studied from a given subject (omniclonal), suggesting common cellular clonal origins of the metastatic cancer cell populations in each of these subjects. Notably, every homozygous deletion identified was within a gene-containing region. Genes affected by clonal homozygous deletions include DOCK5, PTEN, BRCA2, TGFBR2, KAT2B, PGR, FHIT, RERE, HDAC2, PPP2R2A, BNIP3L, CDKN2A, ACVRL1 and others ( Supplementary Table 1 ). The spectrum of anatomic sites affected by metastasis in men with disseminated prostate cancer is variable 21 and might be explained by variations at the genomic level. To examine whether specific clonal or subclonal changes are associated with specific anatomic sites of metastasis 21 , we used permutation-based analyses to compare observed cCGH and Affy6 copy number data from all 85 DNA samples grouped by anatomic location. We found no statistical evidence of copy number pattern similarity on this basis ( Supplementary Figs. 7 and 8 online) .
Prostate cancer is more aggressive at every stage in African-Americans than in other ethnic groups 22 . We used permutation-based analysis to compare copy number findings in prostate cancer samples from four African-American men represented in the cCGH data and two African-American men represented in the Affy6 data. We detected no difference in overall genomic pattern (data not shown), though the results are based on a small sample size.
Androgen pathway alterations are thought to have crucial roles in the progression of prostate cancer to a lethal disease, with upregulation of androgen receptor (AR) gene expression a consistent finding. With respect to AR copy number, we found that only two subjects (subjects 17 and 34) show a normal single copy of AR in all metastatic sites. Seven subjects (subjects 3, 12, 19, 22 and 31-33) showed gains of two to eight copies, with most of them having gains to two or three copies. Five subjects (subjects 16, 21, 24, 28 and 30) show AR copy number gains to 9-40 copies, similar to the high-level gains found in a minority of cases in previous in situ hybridization based studies 23, 24 ( Supplementary Fig. 9 online) . In most subjects AR copy number was relatively stable across metastastic sites, consistent with clonal origins with subclonal variations as seen in the overall copy number analysis ( Supplementary Fig. 9 ).
Fusion transcript formation between TMPRSS2 and ETS family members has been shown to occur in 50% or more of all prostate cancers, with TMPRSS2-ERG fusion transcripts being most commonly found 10 . With regard to TMPRSS2-ERG fusions, we found heterozygous deletion between ERG and TMPRSS2 in seven of fourteen subjects studied by Affy6 ( Supplementary Fig. 10 online) . When it was present, the same deletion event was found in each metastatic site in a given case (data not shown), as previously observed 10 . We examined TMPRSS2-ERG fusion transcript status in 18 anatomically separate metastatic prostate cancer samples from a subset of these subjects, and it was uniformly present in all nine samples studied from subjects with ERG deletion and uniformly absent from all nine samples studied from subjects without ERG deletion (Supplementary Table 2 and Supplementary Fig. 11 online) . These observations are consistent with this deletion and resulting fusion transcript formation being a common early, premetastatic event, although, evidently, one that is not required for successful tumor cell dissemination. A more thorough cataloging of all ETS family gene fusions will be necessary to understand their role in tumor progression. Beyond the demonstrated presence of clonal and subclonal changes in each subject's set of metastatic samples, the overall patterns of genomic change vary greatly between subjects (Fig. 1e) .
To test whether these overall patterns could be related to the therapy received, we compared clonal and subclonal change frequencies (Supplementary Table 3 online) in seven subjects that had undergone DNA-damaging chemotherapy (cylophosphamide, topotecan, etoposide and/or carboplatin) (Supplementary Table 4 online) compared to seven subjects who did not receive DNA-damaging chemotherapy and found no statistical differences ( Supplementary  Figs. 12-14 online) .
To our knowledge, this study provides the first full highresolution genomic overview of copy number changes in multiple metastatic cancers in individual humans, the analysis of which adds substantial depth to the clonal origins discussion. This study provides evidence that all or at least the vast majority of individuals with metastatic prostate cancer have cancers that originated in a single aberrant cell, a finding likely to extend to other cancers, and shows that it is feasible to use metastatic site comparison to derive the set of changes present in the parent cancer cell in each subject. The findings also show that there is a substantial but variable number of subclonally maintained changes in metastatic cancer sites in a given subject.
Our findings cast new light on previously published data suggesting that primary prostate cancers are often multifocal 1-3 and often have multiple separate clonal parent cell origins [4] [5] [6] . Our data show that lethal metastatic prostate cancer cells are derived from a common parent cell and also show that subclonal changes arise and are sustained. Studies of anatomically separate primary cancers from individual subjects using a genome-wide set of loci are necessary to revisit the multifocality question and determine whether previous studies were underpowered and detected subclonally maintained differences but missed clonal changes, or whether primary prostate cancer is often truly multifocal, as is currently widely believed.
Our recent studies of relative hyper-and hypo-methylation at selected CpG islands in the same subjects' samples suggest that some hypermethylation changes are 'clonal' within a given subject 25 , whereas hypomethylation changes are more heterogeneous 26 . These findings, together with transcript and protein expression studies in a similar set of subjects 27 , suggest that full pathway-based integration of genetic, epigenetic and protein data from multiple metastatic samples in a larger series of individuals with metastatic cancer may be a uniquely powerful way to establish well prioritized lists of targets for development of new drug and diagnostic targets.
Several aspects of these data are relevant to tying together what is currently known at the macrogenomic level about metastatic cancer in humans. First, they emphasize that strong evidence of clonal origins does not mean that all cells are genomically identical in a given metastatic cancer site. Cytogenetic and other studies show that a degree of genomic copy number 'wobble' exists in metastatic cancer cells 18 . The data presented here show that despite this wobble, a relatively clean, clear and highly individual-specific pattern of copy number changes occurs in metastatic prostate cancers in the majority of cases, and that this pattern is maintained in aggregate among multiple metastatic sites in individuals with surprising fidelity when compared to cell line-based metastasis studies 28 .
Second, our findings are based on the aggregate signal from millions of metastatic prostate cancer cell genomes represented in each sample studied. It is possible but seems unlikely that two or more clonal populations dependent upon each other for metastatic success could have quite different copy number changes that sum to the data we observe here. Third, these data cannot rule out an alternative hypothesis where clonal-appearing and individually unique copy number patterns observed could be a result of individual subject-specific requirements for successful metastasis. In this alternate scenario, polyclonal, highly genomically unstable cancer cells would succeed only if they met very tight copy number gain and loss requirements specific to the subject. It is hard to imagine a feasible biological mechanism through which such specificity could arise from autochthonous cells, so this hypothesis seems unlikely to be correct. Finally, if in most men metastatic prostate cancer cells have a common clonal origin, this suggests that cancer cells with stem cell properties obtain these properties in the context of a shared set of individualspecific copy number changes, consistent with recent findings 29 . Figure 4 Potential patterns of metastatic prostate cancer spread. Our results show that most, if not all, metastatic prostate cancers have clonal origins. With each 'X' representing a separate anatomic site of metastasis in subject 17, and taking into account recent data suggesting that in some men prostate cancer cells may lie dormant in the bone marrow for many years 30, 31 , spread of cancer cells with common clonal origins occurs in a direct clonal or indirect clonal pattern, as indicated. The large tan circle represents the prostate, and the black circle represents prostate cancers capable of lethal spread. Green circles represent local prostate cancers incapable of spread, and yellow circles represent nonlethal spreading cancer as suggested previously 30 . Dashed arrows indicate prostate cancer metastasis back to the prostate. Direct clonal spread from a primary prostate cancer focus is the simplest model based on our study data from metastatic cancers and prostate cancer found in the prostate at autopsy.
Our results show that metastatic prostate cancer deposits in individual men have clonal origins in most, if not all, cases. Using subject A17 as representative of all subjects in the current study, and considering reports suggesting that prostate cancer cells may lie dormant in the bone marrow for many years 30, 31 , we observed that spread of cancer cells with common clonal origins occurs either in a 'direct clonal' or 'indirect clonal' pattern ( Fig. 4) . We found no significant difference in copy number patterns in prostate cancer foci isolated from the prostate at autopsy and metastases from various sites in the five subjects in whom prostate cancer foci were isolated from the prostate at autopsy. Direct clonal lethal metastasis provides the simplest explanation of these findings, as indirect metastasis would require that the metastatic prostate cancer metastasize back to the prostate.
In conclusion, these data suggest that in most, if not all, metastatic prostate cancer cases, the origins of cancer cells within disparate metastatic prostate cancer deposits can be traced to a single genomically aberrant prostate cell whose macrogenomic copy number changes are relatively stably replicated with each cell division. Upon this relatively stable base of copy number change, additional copy number changes occur and are subclonally sustained. These findings have potentially crucial implications for treatment of metastatic prostate cancer-understanding and predicting therapeutic success in an individual will probably depend on the degree of clonal uniformity as well as the specific genomic alteration pattern for metastatic lesions in a given patient. Hypothetically, because high clonal diversity should improve cancer cell survival in response to change, the degree of clonality of a given patient's metastatic prostate cancer cells could have as important an impact on therapeutic response as the specific pattern of genomic changes found in the prostate cancer cells. Additional studies are needed to determine how the macrogenomic monoclonality suggested in the majority of subjects with metastatic prostate cancer studied here relates to what is found at the microgenomic (individual base pair) level.
METHODS
Project to Eliminate Lethal Prostate Cancer autopsy study. We studied 94 cancer samples from 30 men who died of prostate cancer and underwent autopsy as part of the Project to Eliminate Lethal Prostate Cancer (PELICAN) rapid autopsy program at the Johns Hopkins Autopsy Study of lethal Prostate Cancer (JHASPC) initiated in 1994. All JHASPC study subjects gave informed consent to participate as part of a Johns Hopkins Medicine Institutional Review Board-approved protocol. All subjects underwent androgen deprivation during the course of their treatment for metastatic prostate cancer and died between 1995 and 2004. We snap-froze tissues, microdissected them with a cryostat and purified DNA as described previously 20 . Subject and sample data, including distribution of samples studied by cCGH and Affy6 array technology, are contained in Supplementary Tables 5 and 6 online. The mean estimated cancer sample DNA purity, based on H&E histology, is 88% (range 60-99%).
Chromosomal comparative genomic hybridization. We performed cCGH at a resolution of 389 cytogenetic bands (excluding the Y chromosome) in 85 cancer DNA samples from 29 subjects. cCGH data (Supplementary Table 7 online) are of lower resolution than but highly concordant with array-based CGH results 32 . We performed cCGH as described previously 33 and with analysis as detailed in Supplementary Methods and Supplementary Tables 8  and 9 online.
Affymetrix Genome-Wide human single nucleotide polymorphism Array 6.0 analysis. We purchased Affy6 chips from Affymetrix. We obtained all of the reagents used for the assay from manufacturers recommended by Affymetrix in the user guide for the Affy6 chip. We amplified, purified, fragmented and labeled the genomic DNA and hybridized it to Affy6 arrays, which we washed and stained according to the manufacturer's instructions (Supplementary Methods). We used Partek Genomic Suite (PGS) version 6.4 for allele specific and non-allele-specific analyses using default settings unless otherwise specified. We used 16 subject-paired noncancerous samples from 14 subjects to create a copy number baseline ( Supplementary Table 6 ). For each of 58 cancer DNA samples studied by Affy6, we then generated a DNA copy number estimate for all B1.8 million probes on the Affy6 chip and segmented these data into 52,221 channels with the PGS Segmentation algorithm. We then analyzed the autosomal and sex-chromosomal segmentation data for the 58 samples in PGS by unsupervised hierarchical clustering (Pearson's dissimilarity algorithm) to produce the data shown in Figure 1e . We performed allelespecific genomic analysis (Figs. 2 and 3 and Supplementary Table 1 ) with the PGS allele-specific analysis algorithm that includes genotype information and allele-specific intensities from paired samples to estimate DNA copy number for each heterozygous SNP (Supplementary Methods).
Statistical analyses. For the cCGH data, we considered each metastatic DNA sample with 218 SAM-defined (Supplementary Methods and Supplementary  Tables 8 and 9 ) CGH measures as a vector of 218 elements, and we defined the distance between two samples as the euclidean distance of two vectors. For the Affy6 data, we considered each metastatic DNA sample with 52,221 measures as a vector of 52,221 elements, and we defined the distance between two samples as the euclidean distance of two vectors. We divided all of the samples into a training set and a testing set. We defined the predicted label for a sample in the testing set as the same as the label of the sample mean of all samples belonging to the same subject in the training set with the smallest distance to the testing sample (nearest mean classifier) 13 . We then performed leave-one-out cross validation with one sample as the test sample and the remaining samples as the training set 13 . We repeated this such that every sample was used once as testing sample. If the predicted label coincided with the original label, it was correctly classified; otherwise, it was in error. We applied the nearest mean classification method to classify the samples and used the leave-one-out cross validation to estimate the classification error. We calculated the error rate as the percentile of wrongly classified samples over all samples. Statistical tests on cCGH and Affy6 data are one-tailed.
We also tested cCGH and Affy6 data for evidence of clonality by testing the hypothesis that there is no difference between the 'between-subject' distance and the 'within-subject' distance by considering each cCGH sample with 218 CGH measures as a vector of 218 elements and each Affy6 sample with 52,221 measures as a vector of 52,221 elements. We let D bm be the average betweensubject distance over all sample pairs belonging to different subjects and D bw be the average within-subject distance over all sample pairs belonging to the same subject. Using the summary statistic S s ¼ D bm -D bw , we compared the experimentally observed S s to the distribution of S s calculated from 100,000 random permutations of the subject labels 34, 35 . The experimentally observed cCGH data S s value was 3.8159, and the maximum value of S s in the permuted data was 0.8467 ( Supplementary Fig. 3 ), rejecting the null hypothesis with P o 0.00001. The experimentally observed Affy6 data S s value was 110.24, and the maximum value of S s in the permuted data was 19.62 ( Supplementary  Fig. 6 ), rejecting the null hypothesis with P o 0.00001. Additional statistical methods are detailed in Supplementary Tables 10 and 11 In the version of this article initially published, the two right histological sections in Figure 5a were duplicated in Figure 5b . The error has been corrected in the HTML and PDF versions of the article.
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